Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vomiting 6Nausea 3Neoplasms 2Uterine Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Multiple Myeloma 1Melanoma 1Gynecologic Cancer 1Gastrointestinal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Paclitaxel 6Radiotherapy 2Pemetrexed 2Carboplatin 2Brachytherapy 2tucatinib 1seribantumab 1osimertinib 1gedatolisib 1fosaprepitant 1fluciclovine F-18 1cobimetinib 1atezolizumab 1alovudine 1Trastuzumab 1Therapeutics 1TP protocol 1Saline Solution 1Radiation 1Protons 1Palliative Care 1Nivolumab 1Letrozole 1Immunoglobulin G 1Imatinib Mesylate 1Ifosfamide 1Gemcitabine 1Fulvestrant 1FANG vaccine 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Uterine Neoplasms × fosaprepitant × Clear all
NCT01432015 2017-03-28

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

Gynecologic Oncology Associates

Phase 4 Completed
20 enrolled 5 charts
Gynecologic

Ovarian Neoplasms, Uterine Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡